TST105

FGFR2b Bi-Specific

Target:: FGFR2b Bi-Specific

Indication:: Solid tumors

Project Status:: Preclinical

TST105 is a humanized bispecific antibody-based drug conjugate (ADC) targeting FGFR2b and an undisclosed tumor antigen, FGFR2b is a validated tumor antigen overexpressed in gastric cancer, lung cancer and other solid tumors. We are currently developing the bispecific ADC to improve therapeutic window.

• In 2024, we have demonstrated potent anti-tumor activity from in vivo pharmacology studies for the ADC lead molecule selection and additional preclinical studies are ongoing.